Get started
Author

Anne Yver

Observed names: A. Yver, YVER, Anne
OpenAlex ID: A5072089844
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
2022 · Tim H. Brümmendorf, Jorge E. Cortes, et al. · Leukemia · 148
PDF
Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
2023 · Andrew D. Leavitt, Barbara A. Konkle, et al. · Blood · 45
Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
2020 · Tim H Brümmendorf, Jorge E. Cortes, et al. · Blood · 31
MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
2024 · Alexander M. Lesokhin, Muhammed Saleem Raza, et al. · Journal of Clinical Oncology · 5
MagnetisMM-32: Evaluation of Elranatamab Vs EPd, PVd, or Kd in Patients with Relapsed or Refractory Multiple Myeloma and Prior Anti-CD38-Directed Therapy
2024 · Steven Schuster, Satoshi Ito, et al. · Blood · 4
MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma.
2022 · Rafael Fonseca, Junya Kuroda, et al. · Journal of Clinical Oncology · 4
P-017: MagnetisMM-7: an open label, randomized, phase 3 study of elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after transplant
2022 · María-Victoria Mateos, Jae Hoon Lee, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Pb2032: Magnetismm-9: an Open-label, Multicenter, Non-randomized Phase 1/2 Study of Elranatamab in Patients With Relapsed/refractory Multiple Myeloma
2022 · R. Fonseca, J. Kuroda, et al. · HemaSphere · 2
Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38–directed therapy: MagnetisMM-32.
2024 · Steven Robert Schuster, Satoshi Ito, et al. · Journal of Clinical Oncology · 1
MagnetisMM-32: A phase 3 randomized study of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma (RRMM) and prior anti-CD38–directed therapy.
2025 · Steven Robert Schuster, Saulius Girnius, et al. · Journal of Clinical Oncology
PDF
Gene therapy with giroctocogene fitelparvovec for people with severe hemophilia A: a plain language summary of the 2-year results of a 5-year study
2025 · Andrew D. Leavitt, Barbara A. Konkle, et al. · Future Rare Diseases
P-260 MagnetisMM-30: A Phase 1B, Open-Label Study of Elranatamab in Combination With Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
2024 · Alexander Lesokhin, Muhammed Raza, et al. · Clinical Lymphoma Myeloma & Leukemia
MagnetisMM-32: Evaluation of Elranatamab vs EPd, PVd, or Kd in Patients With Relapsed or Refractory Multiple Myeloma and Prior Anti-CD38– Directed Therapy
2024 · Steven R. Schuster, Satoshi Ito, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 14
Citation count: 242
H-index: 4
I10-index: 3
Year
Topic
Type